BRAF and neoplasm: Small-molecule inhibitors of mutated BRAF (BRAFV600E/K), such as vemurafenib (PLX4032) and dabrafenib (GSK2118436), already proved to have marked anti-tumour activity in melanomas harbouring such a BRAF mutation and consequently achieve prolonged progression-free and overall survival in these patients [4, 5].